Thanks, Donald. indie delivered a strong third quarter, once again on plan and producing record results. In fact, Q3 represents our sixth consecutive quarter of beating or at least meeting our guidance, post indie's IPO last summer. Revenue for the period was up 147% year-over-year and 17% sequentially to $30 million. Gross profit was $15.1 million, translating into a 50.4% gross margin, up 740 basis points year-over-year and 180 basis points sequentially and above our 50% guidance. To put this performance in better context, when we announced our plans to IPO in Q4 2020, indie was at just $6.7 million in quarterly revenue with a 35.4% gross margin. Since then, and despite global supply chain constraints, we successfully scaled our business nearly five-fold and increased our gross margin by 1,500 basis points in less than 24 months. Turning back to Q3 results. Operating expenses were $30.9 million, slightly better than our guidance for $31 million. In particular, R&D investments were $24.2 million in support of accelerated product development, while SG&A of $6.7 million reflects continued investments to further extend our sales reach. As a result, our Q3 operating loss was $15.8 million. Interest and other income yielded $0.5 million and taxes were negligible. In turn, our net loss was $15.3 million with a net loss per share of $0.10 on a base of 150.7 million shares, $0.01 better than our guidance. Turning to the balance sheet. We exited the period with $150.8 million of cash and limited debt. During the quarter, we invested $9.9 million in working capital, including onetime inventory prepayments and IP licenses. Capital expenditures were $2.7 million in support of expanded lab equipment and global IT infrastructure. Finally, and as an offset, we raised $12 million through the sale of 1.5 million shares under our ATM program. Looking forward, based on the depth of our new product pipeline, we plan to maintain outsized top line growth while further expanding our gross margin over the planning horizon. Specifically, for the fourth quarter of 2022, we anticipate sales growth to an approximately $132 million annualized revenue run rate with gross margin expansion into the 51% range. We are planning nominal increases in operating expenses with $25 million in R&D for additional mass sets and $7 million of SG&A for incremental marketing investments, but further reductions, again, on a percent of sales basis. Below the line, we anticipate a pickup of $750,000 of net interest income and no taxes. Assuming 152 million shares outstanding, we expect a net loss of $0.09 per share, once again, a $0.01 better than consensus estimates. Further, and perhaps most importantly, given our strong order visibility, demonstrated scalability and planned operating expense leverage, we are on track to reach profitability in the second half of next year with narrowing losses from here, representing key next steps towards realizing our 60% gross and 30% operating margin target model. With that, I'll turn the call back to Donald for his closing comments.